JP5600056B2 - レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤 - Google Patents

レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤 Download PDF

Info

Publication number
JP5600056B2
JP5600056B2 JP2010280325A JP2010280325A JP5600056B2 JP 5600056 B2 JP5600056 B2 JP 5600056B2 JP 2010280325 A JP2010280325 A JP 2010280325A JP 2010280325 A JP2010280325 A JP 2010280325A JP 5600056 B2 JP5600056 B2 JP 5600056B2
Authority
JP
Japan
Prior art keywords
levofloxacin
ophthalmic solution
eye
dosage
genus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010280325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011195564A (ja
Inventor
敬 長野
浩二 阪中
雅胤 中村
剛一 河津
肇 伊吹
佳代子 坂本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd, Daiichi Sankyo Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Priority to JP2010280325A priority Critical patent/JP5600056B2/ja
Publication of JP2011195564A publication Critical patent/JP2011195564A/ja
Application granted granted Critical
Publication of JP5600056B2 publication Critical patent/JP5600056B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2010280325A 2010-02-25 2010-12-16 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤 Active JP5600056B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010280325A JP5600056B2 (ja) 2010-02-25 2010-12-16 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010040281 2010-02-25
JP2010040281 2010-02-25
JP2010280325A JP5600056B2 (ja) 2010-02-25 2010-12-16 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012054761A Division JP2012162532A (ja) 2010-02-25 2012-03-12 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する結膜炎治療用点眼剤

Publications (2)

Publication Number Publication Date
JP2011195564A JP2011195564A (ja) 2011-10-06
JP5600056B2 true JP5600056B2 (ja) 2014-10-01

Family

ID=44506417

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010280325A Active JP5600056B2 (ja) 2010-02-25 2010-12-16 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤
JP2012054761A Pending JP2012162532A (ja) 2010-02-25 2012-03-12 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する結膜炎治療用点眼剤
JP2013169146A Active JP5674882B2 (ja) 2010-02-25 2013-08-16 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する結膜炎治療用点眼剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012054761A Pending JP2012162532A (ja) 2010-02-25 2012-03-12 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する結膜炎治療用点眼剤
JP2013169146A Active JP5674882B2 (ja) 2010-02-25 2013-08-16 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する結膜炎治療用点眼剤

Country Status (16)

Country Link
US (1) US20120316158A1 (https=)
EP (1) EP2540299B1 (https=)
JP (3) JP5600056B2 (https=)
KR (2) KR20130043611A (https=)
CN (1) CN102770141A (https=)
BR (1) BR112012021247A2 (https=)
CA (1) CA2791190C (https=)
EA (1) EA201290827A1 (https=)
ES (1) ES2568647T3 (https=)
MX (1) MX349603B (https=)
MY (1) MY183483A (https=)
NZ (1) NZ602126A (https=)
PH (2) PH12016501747B1 (https=)
SG (1) SG183427A1 (https=)
TW (1) TWI488627B (https=)
WO (1) WO2011104981A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013241464A (ja) * 2010-02-25 2013-12-05 Santen Pharmaceut Co Ltd レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する結膜炎治療用点眼剤

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103550144B (zh) * 2013-10-25 2015-10-14 深圳朗欧医药集团有限公司 盐酸左氧氟沙星组合物注射液及其制备方法
JP6363833B2 (ja) * 2013-11-22 2018-07-25 ナノシータ株式会社 薄膜状高分子構造体
CN104606198A (zh) * 2015-01-09 2015-05-13 周元铎 盐酸左氧氟沙星在制备防治家蚕细菌性败血病药中的应用
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3038722B2 (ja) 1989-06-23 2000-05-08 日本電気株式会社 接合型電界効果トランジスタ
JP3192290B2 (ja) 1993-08-04 2001-07-23 カネボウ株式会社 ポリエステル製耐熱ボトル
WO2003028664A2 (en) * 2001-10-03 2003-04-10 Teva Pharmaceutical Industries Ltd. Preparation of levofloxacin and forms thereof
EP1458391B1 (en) * 2001-11-30 2007-09-05 LG Life Sciences Ltd. A method of treating bacterial infections using gemifloxacin or a salt thereof and a beta-lactam antibiotic
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
WO2005000307A1 (en) * 2003-06-26 2005-01-06 Santen Pharmaceutical Co., Ltd. Ophthalmic composition containing quinolones and method of use
ES2671342T3 (es) * 2006-02-10 2018-06-06 Pari Pharma Gmbh Antibióticos nebulizados para terapia de inhalación
WO2008005276A2 (en) * 2006-06-30 2008-01-10 Directcontact Llc Growth factor delivery system containing antimicrobial agents
EP2143422A1 (en) * 2008-07-11 2010-01-13 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections
PH12016501747B1 (en) * 2010-02-25 2022-06-22 Daiichi Sankyo Co Ltd Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and the use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013241464A (ja) * 2010-02-25 2013-12-05 Santen Pharmaceut Co Ltd レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する結膜炎治療用点眼剤

Also Published As

Publication number Publication date
SG183427A1 (en) 2012-09-27
NZ602126A (en) 2013-10-25
WO2011104981A1 (ja) 2011-09-01
MX2012009844A (es) 2012-09-21
PH12016501747A1 (en) 2019-02-11
JP2013241464A (ja) 2013-12-05
KR20130043611A (ko) 2013-04-30
JP5674882B2 (ja) 2015-02-25
EA201290827A1 (ru) 2013-03-29
EP2540299A4 (en) 2013-07-24
CN102770141A (zh) 2012-11-07
BR112012021247A2 (pt) 2018-04-03
AU2010346703A1 (en) 2012-09-20
ES2568647T3 (es) 2016-05-03
TWI488627B (zh) 2015-06-21
CA2791190C (en) 2017-12-12
KR20170070265A (ko) 2017-06-21
JP2011195564A (ja) 2011-10-06
PH12012501674A1 (en) 2012-11-05
PH12016501747B1 (en) 2022-06-22
US20120316158A1 (en) 2012-12-13
EP2540299A1 (en) 2013-01-02
EP2540299B1 (en) 2016-04-13
CA2791190A1 (en) 2011-09-01
MX349603B (es) 2017-08-03
MY183483A (en) 2021-02-20
TW201129364A (en) 2011-09-01
JP2012162532A (ja) 2012-08-30
HK1177887A1 (en) 2013-08-30

Similar Documents

Publication Publication Date Title
JP5674882B2 (ja) レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する結膜炎治療用点眼剤
KR102649858B1 (ko) 안질환의 치료를 위한 조성물 및 방법
WO2016072440A1 (ja) 眼科用水性組成物
Matsuura et al. Conjunctival bacterial flora and antimicrobial susceptibility in bacterial pathogens isolated prior to cataract surgery
Tabbara et al. Treatment of acute bacterial conjunctivitis with topical lomefloxacin 0.3% compared to topical ofloxacin 0.3%
WO2016196989A1 (en) Topical composition
HK1177887B (en) Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof
HK1178045A (en) Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof
RU2293563C1 (ru) Способ лечения инфекционных воспалительных заболеваний глаз
Adamiec-Mroczek et al. Efficient antiseptic prophylaxis in the era of antibiotic resistance
CN103735499A (zh) 一种盐酸尤利沙星滴眼液及其制备方法
WO2024105689A1 (en) Novel ophthalmic composition
AKANDA et al. Efficacy of Perioperative Oral Antibiotics in the Prevention of Acute Infective Endophthalmitis after SICS
WO2025229666A1 (en) Novel ophthalmic gel composition
JP2022186865A (ja) アルキルジアミノエチルグリシンまたはその塩を含有する水性点眼液
RU2549472C1 (ru) Фармацевтическая композиция в форме капель для профилактики и лечения аллергических заболеваний глаз
Stevens et al. Fluoroquinolones for the treatment of microbial infections
CN101385728A (zh) 一种巴洛沙星或其盐的滴眼液制剂及其制备方法
WO2022107789A1 (ja) 塩化ポリドロニウムを含有する水性点眼液
Hariprasad et al. of Endophthalmitis
Hariprasad et al. Evidence-Based Medicine: The Prophylaxis and Treatment of Endophthalmitis
JP2004049228A (ja) 麦粒腫の病態モデル動物およびその作製方法

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110922

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120312

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120509

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140814

R150 Certificate of patent or registration of utility model

Ref document number: 5600056

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250